Recurrent Childhood Acute Lymphoblastic Leukemia Completed Phase 1 Trials for BMS-214662 (DB12234)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00006213BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaTreatment